ERBB2 and breast carcinoma: Relevant to cancer immunotherapy, CD16-expressing γδ T cells have been shown to improve the efficacy of therapeutic antibodies such as rituximab and trastuzumab for the treatment of lymphoma, chronic lymphocytic leukemia, and human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells (54, 55).